The University of Chicago Header Logo

Megan Mcnerney

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentPathology
AddressChicago IL 60637
Phone+1 (773) 834-8896
Email
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    The McNerney lab studies the genomic changes in blood cancers with the goal of identifying therapeutic vulnerabilities. We focus on myeloid malignancies which are particularly difficult to treat. We apply a variety of functional genomics approaches and model systems to decipher changes in the cancer genome. Ongoing and available projects include studies of hematopoietic stem cell regulation, gene regulation during hematopoiesis, contiguous gene syndromes in cancer, and oncogenic signaling. Please visit our webpage for more information https://voices.uchicago.edu/mcnerneylab/
    Collapse webpage

    Collapse Biography 
    Collapse education and training
    Northwestern University, EvanstonB.A.1999Molecular and Cellular Biology
    The University of Chicago, ChicagoPhD2005Immunology
    The University of Chicago , ChicagoMD2007Medicine
    The University of Chicago, ChicagoResidency2010Clinical Pathology
    The University of Chicago, ChicagoPostdoctoral2014Genomics and Systems Biology
    Collapse awards and honors
    1997Edgar Macey Scholarship for Summer Research, Northwestern University
    1999Graduation with Departmental Honors, Biological Sciences, Northwestern University
    1999Graduation Cum Laude, Northwestern University
    2000 - 2007Medical Scientist Training Program, NIH
    2003Elaine Frank Family Fellowship for Medical Research, MSTP, University of Chicago
    2004Doolittle-Harrison Travel Fellowship, University of Chicago
    2005Robert E. Priest Pathology Merit Award, Department of Pathology, University of Chicago
    2006Honorable Mention Best PhD Dissertation Award, Biological Sciences, University of Chicago
    2006Committee on Immunology Best PhD Thesis Award, University of Chicago
    2007Leon Jacobson Prize for Senior Scientific Presentation, Pritzker School of Medicine
    2009Resident Research Grant, College of American Pathologists
    2010Robert W. Wissler Fellowship Award, Department of Pathology
    2011Leukemia and Lymphoma Society Fellow Award
    2013Leukemia and Lymphoma Society, Illinois Chapter Researcher of the Year
    2013Evans Travel Award, FASEB Hematologic Malignancies Science Research Conference
    2013Cancer Research Foundation Young Investigator Award
    2014“V” Foundation in Cancer Research Scholar Award
    2015Nachman Fellow, Dept. of Pediatrics Hematology-Oncology
    2017American Society of Hematology Junior Faculty Scholar Award
    2019American Cancer Society Research Scholar Award
    2020Faculty Award for Excellence in Graduate Teaching and Mentoring
    2022Leukemia and Lymphoma Society Scholar Award

    Collapse Research 
    Collapse research activities and funding
    R01HL166184     (MCNERNEY, MEGAN)Dec 1, 2022 - Nov 30, 2026
    NIH
    Establishing CUX1 as a determinant of hematopoietic stem cell fate
    Role: Principal Investigator

    R01CA231880     (MCNERNEY, MEGAN)Sep 20, 2018 - Aug 31, 2023
    NIH
    The pathogenesis of chromosome 7q deletions in juvenile myelomonocytic leukemia
    Role: Principal Investigator

    R01HL142782     (MCNERNEY, MEGAN)Jul 15, 2018 - Jun 30, 2023
    NIH
    Regulation of hematopoiesis by CUX1
    Role: Principal Investigator

    K08CA181254     (MCNERNEY, MEGAN ELIZABETH)Sep 16, 2014 - Aug 31, 2019
    NIH
    Determining the role of CUX1 in myeloid neoplasia
    Role: Principal Investigator

    F32CA150631     (MCNERNEY, MEGAN ELIZABETH)Dec 1, 2010 - Jun 30, 2011
    NIH
    Next-Generation Sequencing of Therapy-Related Acute Myeloid Leukemia
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kaur A, Rojek AE, Symes E, Nawas MT, Patel AA, Patel JL, Sojitra P, Aqil B, Sukhanova M, McNerney ME, Wu LP, Akmatbekov A, Segal J, Tjota MY, Gurbuxani S, Cheng JX, Yeon SY, Ravisankar HV, Fitzpatrick C, Lager A, Drazer MW, Saygin C, Wanjari P, Katsonis P, Lichtarge O, Churpek JE, Ghosh SB, Patel AB, Menon MP, Arber DA, Wang P, Venkataraman G. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 Jun 18; 14(1):99. PMID: 38890297; PMCID: PMC11189545.
      Citations:    Fields:    Translation:Humans
    2. Liu W, Kurkewich JL, Stoddart A, Khan S, Anandan D, Gaubil AN, Wolfgeher DJ, Jueng L, Kron SJ, McNerney ME. CUX1 regulates human hematopoietic stem cell chromatin accessibility via the BAF complex. Cell Rep. 2024 May 28; 43(5):114227. PMID: 38735044; PMCID: PMC11163479.
      Citations:    Fields:    Translation:HumansAnimalsCells
    3. Martinez TC, McNerney ME. Haploinsufficient Transcription Factors in Myeloid Neoplasms. Annu Rev Pathol. 2024 Jan 24; 19:571-598. PMID: 37906947.
      Citations:    Fields:    Translation:Humans
    4. An N, Khan S, Imgruet MK, Jueng L, Gurbuxani S, McNerney ME. Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells. Oncogene. 2023 03; 42(12):881-893. PMID: 36725889; PMCID: PMC10068965.
      Citations: 3     Fields:    Translation:AnimalsCells
    5. Shih AJ, Jun T, Skol AD, Bao R, Huang L, Vora S, McNerney ME, Hungate EA, Le Beau MM, Larson RA, Elliott A, Lu HM, Huether R, Hernandez F, Allan JM, Onel K, Stölzel F. Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms. Br J Haematol. 2023 02; 200(4):489-493. PMID: 36349721; PMCID: PMC11246702.
      Citations: 1     Fields:    Translation:Humans
    6. Stoddart A, Fernald AA, Davis EM, McNerney ME, Le Beau MM. EGR1 Haploinsufficiency Confers a Fitness Advantage to Hematopoietic Stem Cells Following Chemotherapy. Exp Hematol. 2022 11; 115:54-67. PMID: 35995095; PMCID: PMC10617250.
      Citations:    Fields:    Translation:HumansAnimalsCells
    7. Jotte MRM, McNerney ME. The significance of CUX1 and chromosome 7 in myeloid malignancies. Curr Opin Hematol. 2022 03 01; 29(2):92-102. PMID: 35084368; PMCID: PMC8795693.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    8. Baeten JT, Liu W, Preddy IC, Zhou N, McNerney ME. CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions. Leukemia. 2022 05; 36(5):1421-1425. PMID: 35034954; PMCID: PMC9064908.
      Citations: 3     Fields:    Translation:HumansCells
    9. Krishnan M, Senagolage MD, Baeten JT, Wolfgeher DJ, Khan S, Kron SJ, McNerney ME. Genomic studies controvert the existence of the CUX1 p75 isoform. Sci Rep. 2022 01 07; 12(1):151. PMID: 34997000; PMCID: PMC8741762.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    10. Ludwig LM, Hawley KM, Banks DB, Thomas-Toth AT, Blazar BR, McNerney ME, Leverson JD, LaBelle JL. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death Dis. 2021 10 27; 12(11):1005. PMID: 34707089; PMCID: PMC8551340.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    11. Imgruet MK, Lutze J, An N, Hu B, Khan S, Kurkewich J, Martinez TC, Wolfgeher D, Gurbuxani SK, Kron SJ, McNerney ME. Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood. 2021 09 02; 138(9):790-805. PMID: 34473231; PMCID: PMC8414261.
      Citations: 8     Fields:    Translation:AnimalsCells
    12. Imgruet MK, Lutze J, An NN, Hu B, Khan S, Kurkewich J, Martinez TC, Wolfgeher DJ, Gurbuxani S, Kron SJ, McNerney ME. Loss of a 7q gene, CUX1, disrupts epigenetic-driven DNA repair and drives therapy-related myeloid neoplasms. Blood. 2021 May 26. PMID: 34041524.
      Citations:    
    13. Stoddart A, Wang J, Fernald AA, Davis EM, Johnson CR, Hu C, Cheng JX, McNerney ME, Le Beau MM. Cytotoxic Therapy-Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms. Blood Cancer Discov. 2020 07; 1(1):32-47. PMID: 32924016; PMCID: PMC7486063.
      Citations: 15     Fields:    Translation:AnimalsCells
    14. Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O. A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606. PMID: 32074275; PMCID: PMC7042987.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    15. McNerney ME, Le Beau MM. The Harmful Consequences of Increased Fitness in Hematopoietic Stem Cells. Cell Stem Cell. 2018 11 01; 23(5):634-635. PMID: 30388419.
      Citations: 4     Fields:    Translation:HumansCells
    16. Kang W, Kadri S, Puranik R, Wurst MN, Patil SA, Mujacic I, Benhamed S, Niu N, Zhen CJ, Ameti B, Long BC, Galbo F, Montes D, Iracheta C, Gamboa VL, Lopez D, Yourshaw M, Lawrence CA, Aisner DL, Fitzpatrick C, McNerney ME, Wang YL, Andrade J, Volchenboum SL, Furtado LV, Ritterhouse LL, Segal JP. System for Informatics in the Molecular Pathology Laboratory: An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management. J Mol Diagn. 2018 07; 20(4):522-532. PMID: 29698836; PMCID: PMC6039793.
      Citations: 4     Fields:    Translation:Humans
    17. An N, Khan S, Imgruet MK, Gurbuxani SK, Konecki SN, Burgess MR, McNerney ME. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood. 2018 06 14; 131(24):2682-2697. PMID: 29592892; PMCID: PMC6032890.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    18. McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017 08 24; 17(9):513-527. PMID: 28835720; PMCID: PMC5946699.
      Citations: 137     Fields:    Translation:HumansCellsPHPublic Health
    19. Arthur RK, An N, Khan S, McNerney ME. The haploinsufficient tumor suppressor, CUX1, acts as an analog transcriptional regulator that controls target genes through distal enhancers that loop to target promoters. Nucleic Acids Res. 2017 Jun 20; 45(11):6350-6361. PMID: 28369554; PMCID: PMC5499738.
      Citations: 10     Fields:    Translation:HumansCells
    20. Stricker TP, Brown CD, Bandlamudi C, McNerney M, Kittler R, Montoya V, Peterson A, Grossman R, White KP. Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression. PLoS Genet. 2017 03; 13(3):e1006589. PMID: 28263985; PMCID: PMC5367891.
      Citations: 37     Fields:    Translation:HumansCells
    21. Kadri S, Long BC, Mujacic I, Zhen CJ, Wurst MN, Sharma S, McDonald N, Niu N, Benhamed S, Tuteja JH, Seiwert TY, White KP, McNerney ME, Fitzpatrick C, Wang YL, Furtado LV, Segal JP. Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. J Mol Diagn. 2017 01; 19(1):43-56. PMID: 27836695.
      Citations: 44     Fields:    Translation:Humans
    22. Stoddart A, Qian Z, Fernald AA, Bergerson RJ, Wang J, Karrison T, Anastasi J, Bartom ET, Sarver AL, McNerney ME, Largaespada DA, Le Beau MM. Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica. 2016 06; 101(6):e232-6. PMID: 26944478; PMCID: PMC5013937.
      Citations: 11     Fields:    Translation:AnimalsCells
    23. Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat Genet. 2015 May; 47(5):539-43. PMID: 25822087; PMCID: PMC4414804.
      Citations: 26     Fields:    Translation:AnimalsCells
    24. Wang X, Fu AQ, McNerney ME, White KP. Widespread genetic epistasis among cancer genes. Nat Commun. 2014 Nov 19; 5:4828. PMID: 25407795.
      Citations: 30     Fields:    Translation:HumansCells
    25. Voce DJ, Schmitt AM, Uppal A, McNerney ME, Bernal GM, Cahill KE, Wahlstrom JS, Nassiri A, Yu X, Crawley CD, White KP, Onel K, Weichselbaum RR, Yamini B. Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor. Oncogene. 2015 May 21; 34(21):2807-13. PMID: 25043302; PMCID: PMC4302074.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    26. McNerney ME, Brown CD, Peterson AL, Banerjee M, Larson RA, Anastasi J, Le Beau MM, White KP. The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q). Br J Haematol. 2014 Aug; 166(4):550-6. PMID: 24931631; PMCID: PMC5479678.
      Citations: 14     Fields:    Translation:HumansCells
    27. Heath AP, Greenway M, Powell R, Spring J, Suarez R, Hanley D, Bandlamudi C, McNerney ME, White KP, Grossman RL. Bionimbus: a cloud for managing, analyzing and sharing large genomics datasets. J Am Med Inform Assoc. 2014 Nov-Dec; 21(6):969-75. PMID: 24464852; PMCID: PMC4215034.
      Citations: 22     Fields:    Translation:Humans
    28. Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 2013 Sep; 3(9):993-1001. PMID: 23733505; PMCID: PMC3770749.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    29. Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY, Brägelmann J. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33. PMID: 23490885.
      Citations: 15     Fields:    Translation:HumansCells
    30. McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C, Yu S, Ko J, Sandall BP, Stricker T, Anastasi J, Grossman RL, Cunningham JM, Le Beau MM, White KP. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood. 2013 Feb 07; 121(6):975-83. PMID: 23212519; PMCID: PMC3567344.
      Citations: 76     Fields:    Translation:HumansAnimalsCells
    31. Stoddart A, McNerney ME, Bartom E, Bergerson R, Young DJ, Qian Z, Wang J, Fernald AA, Davis EM, Larson RA, White KP, Le Beau MM. Genetic pathways leading to therapy-related myeloid neoplasms. Mediterr J Hematol Infect Dis. 2011; 3(1):e2011019. PMID: 21713073; PMCID: PMC3113274.
      Citations: 12     
    32. Godley LA, Cunningham J, Dolan ME, Huang RS, Gurbuxani S, McNerney ME, Larson RA, Leong H, Lussier Y, Onel K, Odenike O, Stock W, White KP, Le Beau MM. An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. Semin Oncol. 2011 Apr; 38(2):215-24. PMID: 21421111; PMCID: PMC5591437.
      Citations: 5     Fields:    Translation:HumansCells
    33. McNerney ME, Baron BW, Volchenboum SL, Papari M, Keith M, Williams K, Richa E. Development of warm auto- and allo-antibodies in a 3-year old boy with sickle cell haemoglobinopathy following his first transfusion of a single unit of red blood cells. Blood Transfus. 2010 Apr; 8(2):126-8. PMID: 20383307; PMCID: PMC2851217.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    34. Alegre ML, McNerney ME. Natural killer cell subsets in allograft rejection and tolerance. Curr Opin Organ Transplant. 2007 Feb; 12(1):10-16. PMID: 27792083.
      Citations:    Fields:    
    35. McNerney ME, Lee KM, Zhou P, Molinero L, Mashayekhi M, Guzior D, Sattar H, Kuppireddi S, Wang CR, Kumar V, Alegre ML. Role of natural killer cell subsets in cardiac allograft rejection. Am J Transplant. 2006 Mar; 6(3):505-13. PMID: 16468959.
      Citations: 45     Fields:    Translation:AnimalsCells
    36. McNerney ME, Kumar V. The CD2 family of natural killer cell receptors. Curr Top Microbiol Immunol. 2006; 298:91-120. PMID: 16323413.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    37. Lee KM, Forman JP, McNerney ME, Stepp S, Kuppireddi S, Guzior D, Latchman YE, Sayegh MH, Yagita H, Park CK, Oh SB, Schatzle J, Mathew PA, Sharpe AH, Kumar V, Wülfing C. Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood. 2006 Apr 15; 107(8):3181-8. PMID: 15905190; PMCID: PMC1895752.
      Citations: 36     Fields:    Translation:AnimalsCells
    38. McNerney ME, Guzior D, Kumar V. 2B4 (CD244)-CD48 interactions provide a novel MHC class I-independent system for NK-cell self-tolerance in mice. Blood. 2005 Aug 15; 106(4):1337-40. PMID: 15870174; PMCID: PMC1895194.
      Citations: 16     Fields:    Translation:AnimalsCells
    39. Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol. 2005 May; 5(5):363-74. PMID: 15841099.
      Citations: 54     Fields:    Translation:HumansAnimalsCells
    40. McNerney ME, Lee KM, Kumar V. 2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells. Mol Immunol. 2005 Feb; 42(4):489-94. PMID: 15607804.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    41. Vaidya SV, Stepp SE, McNerney ME, Lee JK, Bennett M, Lee KM, Stewart CL, Kumar V, Mathew PA. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J Immunol. 2005 Jan 15; 174(2):800-7. PMID: 15634901.
      Citations: 42     Fields:    Translation:AnimalsCells
    42. Lee KM, McNerney ME, Stepp SE, Mathew PA, Schatzle JD, Bennett M, Kumar V. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med. 2004 May 03; 199(9):1245-54. PMID: 15123744; PMCID: PMC2211902.
      Citations: 71     Fields:    Translation:AnimalsCells
    43. Yi Y, McNerney M, Datta SK. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol. 2000 Dec 01; 165(11):6627-34. PMID: 11086108.
      Citations: 25     Fields:    Translation:HumansCells
    Mcnerney's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (16)
    Explore
    _
    Co-Authors (42)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _